Chicago's South Side just scored a $50 million bet on its life sciences future, with VectorBuilder announcing plans for a new research and development lab that aims to put the neighborhood squarely on the biotech map. The project is slated to start with about 35,000 square feet of lab and office space, with the company targeting a 2027 opening. For a city that has spent years trying to grow its life-sciences footprint, the move plugs another CDMO-style operator into the mix. Whether this site becomes a true anchor for clinical-grade vector work or adds more bench space to the region will hinge on leasing and hiring decisions that are still ahead.
As reported by the Chicago Business Journal, VectorBuilder plans to invest about $50 million to open and outfit the center, starting with roughly 35,000 square feet on the South Side and aiming for a 2027 launch. The outlet's reporting provides the timeline and square footage figures tied to the company's announcement. The project stands out as one of the larger privately funded lab investments announced for the Chicago area this year.
Who is VectorBuilder?
VectorBuilder is a gene delivery company that offers vector design, viral packaging, and CDMO services for research and clinical clients. In recent years, the firm has broadened into clinical-grade offerings and partnerships that create demand for expanded U.S. R&D and manufacturing footprints. The new South Side lab is framed as the next step in scaling those capabilities.
Where this fits in Chicago's lab market
The announcement lands in the middle of a broader reset in U.S. life-sciences real estate. CBRE Research reported national lab vacancy at roughly 23.2 percent in Q1 2026, and Cushman & Wakefield's Q4 2025 MarketBeat shows vacancy sitting in the low to mid 20s as new construction has slowed. That backdrop helps explain why some owners are rethinking speculative builds even as companies chase capacity for gene and cell therapy work. Local reporting on a large Skokie lab campus hitting the market underscores that Chicago-area life-sciences real estate is in transition; see analysis from CBRE Research, Cushman & Wakefield and Skokie lab campus hits the market.
What to watch next
Developers, prospective tenants and city officials will be watching three things: whether VectorBuilder secures long-term tenants and clinical-grade projects for the space, whether the company hires locally and how quickly the new square footage is absorbed. If the project proceeds on schedule, it will be an early test of demand for mid-sized CDMO and R&D facilities in Chicago as the national lab market works through elevated vacancy and a slower pipeline of speculative development.
